GeneDx Holdings Corp.

GeneDx Holdings Corp. was formed through the business combination of CM Life Sciences III Inc. (Nasdaq: CMLF) with genomic intelligence company Sema4 and rare-disease testing laboratory GeneDx. Sponsored by CM Life Sciences III Sponsor LLC, an entity affiliated with Casdin Capital and Churchill Capital, the SPAC completed its IPO in 2021 and targeted the healthcare and life sciences sector. The combined company filed an S-1 registration statement with the SEC on May 3, 2022, establishing GeneDx Holdings as a publicly registered clinical genomics platform focused on inherited and rare disease diagnostics. Sign up at SpacDesk for complete filing history, sponsor data, and deal analytics on CMLF and the broader SPAC market.